• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
ConclusionsFor stroke prevention in AF, direct OACs seem to be more effective and safer than usual care, and apixaban (5  mg twice daily) had the best profile. For VTE, there was no strong evidence that direct OACs were better than usual care. Education and pharmacist management could improve coagulation control. Both clinicians and patients rated efficacy and safety as the most important factors in managing AF and V TE.Systematic review registrationPROSPERO CRD42017084263 —one deviation; efficacy and safety were from one review.
Source: Systematic Reviews - October 28, 2022 Category: International Medicine & Public Health Source Type: research

Low ‑dose Aspirin for Primary Prevention of Cardiovascular Events in Postmenopausal Women with Type‑2 Diabetes: The Prescriptive Approach in the Real World
Conclusions: Low ‑dose aspirin in our population is prescribed preferentially in postmenopausal women with type‑2 diabetes when affected by metabolic syndrome or metabolic cardiomyopathy, at the opposite women with only high risk have lower chance to receive aspirin.
Source: International Journal of Preventive Medicine - January 2, 2022 Category: International Medicine & Public Health Source Type: research

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - August 19, 2021 Category: International Medicine & Public Health Source Type: research

PCV22 Estimating the Reduction in Medical Care Costs Associated with Ticagrelor and Aspirin in Patients with Acute Ischemic Stroke or TIA
The efficacy of ticagrelor 90mg and aspirin (ticagrelor-aspirin) for the prevention of stroke following an ischaemic stroke (IS) or transient ischaemic attack (TIA) was evaluated in the Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death (THALES, NCT03354429) trial. Ticagrelor-aspirin resulted in a 17% reduction in the risk of stroke or death over 30 days versus aspirin, but with more bleeding events. Ticagrelor 90mg is approved to reduce stroke risk in patients with acute IS (NIH Stroke Scale score ≤5) or high-risk TIA by the Food and Drug Administration.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. McEwan, O. Darlington, M. Knutsson, H. Denison, P. Ladenvall, P. Amarenco, S.C. Johnston, S. Evans, S. James, A. Himmelmann, J. Venditto, C. Mellstrom, N. Atreja, A. Tank Source Type: research

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - April 8, 2021 Category: International Medicine & Public Health Source Type: research

Ticagrelor alone, without aspirin, shows benefit in patients with diabetes
(American College of Cardiology) Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year. The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

Optimal Choice of Pharmacological Therapy – Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation
Conclusions:Novel oral anticoagulants (NOACs) seem to be a better choice as a pharmacological therapy in the treatment of AF, due to a lack of adequate monitoring of patients ’ international normalized ratio (INR) values. CHA2DS2‑VASc and HASBLED scores must be used as a part of routine clinical diagnostics when dealing with patients with AF.Keywords:Atrial fbrillation, hemorrhage, risk, stroke, therapeutics
Source: International Journal of Preventive Medicine - June 3, 2019 Category: International Medicine & Public Health Source Type: research

Stopping aspirin three months after stenting does not increase risk of death
(American College of Cardiology) Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12 inhibitor -- clopidogrel, prasugrel or ticagrelor -- did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. Furthermore, patients who stopped taking aspirin after three months had a significantly lower rate of bleeding.
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news

International study suggests combination therapy may prevent stroke in certain people
(NIH/National Institute of Neurological Disorders and Stroke) Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days. The combination therapy was also associated with an increase in major bleeding, although many of those episodes were non-fatal and did not occur in the brain.
Source: EurekAlert! - Medicine and Health - May 17, 2018 Category: International Medicine & Public Health Source Type: news

PS084 Stroke Due Discontinuance Irregular of Aspirin in Cirurgies Noncardiacs
Acetylsalicylic acid (ASA) is related to higher rate of postoperative bleeding, however, its discontinuity implies increasing cardiovascular disease and increased perioperative mortality.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: J.A.D. Silveira, F.J. Matheus, A. Meneghini, A.L. Queiroz, C.J. Arroyo Neto, A.C.P. Chagas Tags: Poster Abstract Source Type: research

Co-Administration of Proton Pump Inhibitors in Chronic Aspirin Users and the Risk of Adverse Cardiovascular Events: a Population-Based Cohort Study
This study investigated the effect of co-administration of PPIs in aspirin users with a first acute myocardial infarction (AMI) or stroke on the risk of recurrence of such a CV event.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Tran-Duy, FH Vanmolkot, PC Souverein, AW Hoes, A de Boer, CD Stehower, NJ de Wit, MA Joore, F de Vries Source Type: research

Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk
(American Association for Thoracic Surgery) Investigators show that lower dose anticoagulation therapy, combined with low-dose aspirin, resulted in a reduction of 55 to 60 percent of the incidence of adverse bleeding events without significant increases in stroke, transient ischemic attack or total neurological events when used in conjunction with the On-X mechanical aortic valve.
Source: EurekAlert! - Medicine and Health - May 6, 2013 Category: Global & Universal Source Type: news